STAT3 DEGRADERS AND USES THEREOF
The STAT3 degrader, Compound A, effectively targets and degrades STAT3 protein to inhibit tumor growth and overcome drug resistance, showing promise in treating hematological and solid tumors with potent antitumor effects and intermittent dosing strategies.
Patent Information
- Application Number
- JP2024534248
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-11
- Filing Date
- 2022-12-09
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for effective treatments that target STAT3 signaling to suppress tumor growth and overcome drug resistance in cancers, as STAT3 activation is a key driver in various malignancies and contributes to tumor establishment, progression, and resistance to standard therapies.
Development of a STAT3 degrader, Compound A, which selectively targets and degrades STAT3 protein through the ubiquitin-proteasome pathway, formulated into liquid dosage forms for intravenous administration, including a sodium phosphate buffer at pH 6.5, to treat hematological and solid tumors.
Compound A demonstrates potent and selective STAT3 degradation, inducing apoptosis and significant antitumor effects in various cancer cell lines and xenograft models, with potential for intermittent dosing regimens to achieve complete tumor regression and prolonged efficacy.
Smart Images

Figure 2024545125000019 
Figure 2024545125000020 
Figure 2024545125000021
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 63 / 265,275, filed December 11, 2021, and U.S. Provisional Application No. 63 / 383,372, filed November 11, 2022, each of which is incorporated by reference in its entirety herein.
[0002] TECHNICAL FIELD OF THEINVENTION The present invention relates to formulations and dosage forms of the STAT3 degrader (2-(((5S,8S,10aR)-3-acetyl-8-(((S)-5-amino-1-(2-chloro-3-(4-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)phenoxy)-5-oxopentan-2-yl)carbamoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocin-5-yl)carbamoyl)-1H-indole-5-carbonyl)phosphonic acid (Compound A) and methods of use thereof. [Background technology]
[0003] 2. Background of the Invention The ubiquitin-proteasome pathway (UPP) is an important pathway that regulates key regulator proteins and degrades misfolded or abnormal proteins. The UPP is central to many cellular processes and, when deficient or unbalanced, leads to the pathogenesis of various diseases. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases. The UPP plays a major role in the degradation of short-lived regulatory proteins that are important in a variety of fundamental cellular processes, including cell cycle regulation, cell surface receptor and ion channel regulation, and antigen presentation.
[0004] Signal transducer and activator of transcription 3 (STAT3) proteins are activated by cytokines and growth factors upon binding to their cognate cell surface receptors, leading to recruitment and phosphorylation of STAT3 by Janus kinases (JAKs), dimerization, nuclear translocation and transcriptional regulation of STAT3 target genes. In normal cells, STAT3 activity is tightly regulated by feedback control, but in diseases including cancer and autoimmunity, STAT3 activity is deregulated by mechanisms that result in sustained activation of STAT3, as evidenced by high levels of phosphorylated STAT3 (pSTAT3). Approximately 70% of human cancers, including both hematological malignancies and solid tumors, exhibit increased levels of pSTAT3. Aberrant activation of STAT3 has been shown to occur via direct mutation of the STAT3 gene, activation of upstream kinases such as JAK or ALK by mutation or translocation, reduced expression of negative regulators such as SOC3, and elevated receptor signaling from overexpression of cytokines and growth factors in the tumor microenvironment.
[0005] The mechanisms by which deregulated STAT3 contributes to tumor establishment and progression are multifactorial. Among the target genes controlled by STAT3 are key effectors of several hallmarks of cancer, including proliferative signaling (CCND1, CCND2), resisting cell death (BCL2-L1, MCL-1), angiogenesis (VEGF, HIF1α), deregulated cellular energetics (MYC), evading immune destruction (PD-L1, IFNA) and tumor-promoting inflammation (IL-6). In cancer cell models with strong STAT3 activation, such as anaplastic large cell lymphoma (ALCL), genetic knockdown of STAT3 is sufficient to inhibit proliferation and induce apoptosis, confirming the dependency on STAT3 signaling. In addition to these cancer cell-autonomous pathways, activated STAT3 also promotes an inhibitory TME through direct control of immune cell function and regulation of cancer cell-TME crosstalk. Activation of STAT3 in innate and adaptive immune cells generally favors the expansion of immunosuppressive cells while reducing the proliferation, maturation, and function of cytolytic effector cells. Targeting STAT3 with antisense oligonucleotides, which are preferentially taken up by myeloid cells, has been shown to reverse immune suppression and restore the antitumor activity of cytotoxic T cells in mouse syngeneic tumor models. Finally, STAT3 has been shown to be activated in response to both chemotherapy and targeted therapies, such as EGFR inhibitors, contributing to the development of drug resistance. Taken together, these data indicate the importance of STAT3 signaling for tumor establishment and growth, tumor-extrinsic immune suppression in the TME, and the development of resistance to standard therapies, thereby suggesting that selective degradation of STAT3 may be an effective means to suppress STAT3 signaling for the treatment of cancer.
[0006] There is a need to develop dosing and schedules for STAT3 degraders to improve the effectiveness of STAT3 inhibitors and other therapies and to provide single agent activity in cancer treatment. Summary of the Invention [Means for solving the problem]
[0007] Summary of the Invention STAT3 degrader (2-(((5S,8S,10aR)-3-acetyl-8-(((S)-5-amino-1-(2-chloro-3-(4-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl It has been found that )phenoxy)-5-oxopentan-2-yl)carbamoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocin-5-yl)carbamoyl)-1H-indole-5-carbonyl)phosphonic acid (Compound A), as well as salts, formulations and unit dosage forms thereof, as described herein, have certain advantages in treating hematological and solid tumors.
[0008] Thus, in one aspect, the present disclosure provides a liquid formulation or unit dosage form comprising Compound A or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient and / or carrier. In some embodiments, the liquid formulation or unit dosage form of the present invention comprises a sodium phosphate buffer. In some embodiments, the liquid formulation or unit dosage form of the present invention has a pH of about 6.5.
[0009] In another aspect, the present invention provides a method and use for treating a hematological malignancy or solid tumor in a patient, comprising administering to said patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, or a liquid formulation thereof, as described herein. In some embodiments, the hematological malignancy or solid tumor is a relapsed or refractory lymphoma. In some embodiments, the hematological malignancy or solid tumor is selected from large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).
[0010] In some examples, the method includes administering up to about 3.0 mg / kg of Compound A or a pharma- ceutically acceptable salt thereof to the patient per day. In other examples, the method includes administering up to about 500 mg of Compound A or a pharma- ceutically acceptable salt thereof to the patient per day. In some embodiments, the method includes intravenously administering Compound A or a pharma- ceutically acceptable salt thereof to the patient. In some embodiments, the method includes administering Compound A or a pharma- ceutically acceptable salt thereof to the patient once a week (QW). In some embodiments, the method includes administering Compound A or a pharma- ceutically acceptable salt thereof to the patient on days 1, 8, 15, and 22 of a 28-day cycle.
[0011] In some embodiments, the disclosure provides a compound that is Compound A ammonium hydrogen salt.
[0012] These and other aspects of the present disclosure will become apparent upon reference to the following detailed description, to which end various references are set forth herein which describe in more detail certain background information and procedural steps, each of which is incorporated herein by reference in its entirety. [Brief description of the drawings]
[0013] [Figure 1] 1A and 1B show the antitumor activity of Compound A following QW and Q2W intravenous administration in NOD SCID mice bearing SU-DHL-1 xenografts.
[0014] [Diagram 2] FIG. 2A and FIG. 2B show the antitumor activity of Compound A following QW, 2 days on / 5 days off, and Q2W intravenous administration in NOD SCID mice bearing SUP-M2 xenografts.
[0015] [Diagram 3] FIG. 3 illustrates a schematic diagram of a drug product manufacturing process.
[0016] [Figure 4] Figure 4 illustrates a schematic of the Phase 1 study design. *Solid tumors only apply to the MTD / RP2D validation cohort. **RP2D is not always the same as the MTD.
[0017] [Diagram 5] FIG. 5 shows PK data from four patients enrolled on DL1.
[0018] [Figure 6] FIG. 6 shows STAT3 degradation in blood at DL1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] Detailed Description of Specific Embodiments 1. General Description of Certain Embodiments of the Invention: Compound A is a potent, highly selective, intravenously administered heterobifunctional small molecule therapeutic that targets the protein STAT3 and the E3 ligase von Hippel-Lindau protein (VHL) to mediate selective degradation of STAT3 via the ubiquitin-proteasome system (UPS).
[0020] Compound A demonstrated potent and selective STAT3 proteolytic and antitumor activity in a series of in vitro and in vivo studies. In vitro, Compound A degraded STAT3 in human ALCL cell lines SU-DHL-1 and SUP-M2 at the low nanomolar concentration range (≦11.8±2.3 nM), consistent with findings in cell phenotypic assays where Compound A exhibited GI50s of 8.1 nM to 57.4 nM in several ALCL cell lines. Degradation of STAT3 in ALCL lines also induced caspase 3 / 7 activity, a marker of apoptosis, at similar concentrations. Washout experiments in the SU-DHL-1 cell line demonstrated irreversible growth inhibition that occurred after sustained degradation of STAT3 for approximately 48 hours. In a SU-DHL-1 tumor xenograft mouse model, a 10 mg / kg QW dose of Compound A demonstrated significant antitumor efficacy, with all mice in the treatment arm achieving complete regression (Figure 1A). At this dose, over 90% STAT3 degradation in tumors was observed for 48 hours. These data, combined with the results from the in vitro washout study, suggest that a relatively short period of STAT3 degradation is sufficient to induce antitumor effects, supporting the feasibility of relatively short exposures and intermittent dosing regimens in the clinic. Compound A demonstrated comparable potency of degradation of STAT3 in hepatocytes across humans, rats and dogs. PK / PD studies in rats also demonstrated significant degradation of STAT3 protein in multiple tissues following IV administration of Compound A. These data support the selection of rats and dogs as nonclinical species for safety evaluation of Compound A. In a proteome-wide evaluation, Compound A is a highly selective STAT3 degrader that does not degrade other STAT family members or other cellular proteins expressed in peripheral blood mononuclear cells (PBMCs).
[0021] Thus, in some embodiments, the present disclosure provides a method for treating a hematological malignancy or solid tumor in a patient, such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), comprising administering to the patient a therapeutically effective amount of compound A, or a pharma- ceutical acceptable salt thereof, as described herein, or a liquid formulation thereof.
[0022] In some embodiments, the disclosure provides a method for treating a hematological malignancy in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, as described herein, or a liquid formulation thereof.
[0023] In some embodiments, the disclosure provides a method for treating relapsed or refractory lymphoma in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, as described herein, or a liquid formulation thereof.
[0024] In some embodiments, the disclosure provides a method for treating a solid tumor in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, as described herein, or a liquid formulation thereof.
[0025] In some embodiments, the present disclosure provides a method for treating LGL-L in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, as described herein, or a liquid formulation thereof.
[0026] In some embodiments, the disclosure provides a method for treating PTCL in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutical acceptable salt thereof, as described herein, or a liquid formulation thereof.
[0027] In some embodiments, the disclosure provides a method for treating CTCL in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, as described herein, or a liquid formulation thereof.
[0028] In some embodiments, the disclosure provides a liquid formulation comprising Compound A or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient and / or carrier. In some embodiments, the disclosure provides a unit dosage form comprising Compound A or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient and / or carrier.
[0029] In the following disclosure, certain specific details are described to provide a thorough understanding of the various embodiments. However, those skilled in the art will understand that the methods and uses described herein may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context otherwise requires, throughout this specification and the following claims, the word "comprise" and variations thereof, such as "comprises" and "comprising," should be construed in an open-ended inclusive sense, i.e., "including, but not limited to." Additionally, the headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.
[0030] References throughout this specification to "one embodiment" or "an embodiment" mean that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Thus, the appearances of the terms "in one embodiment" or "in an embodiment" in various places throughout this specification do not necessarily all refer to the same embodiment. Furthermore, particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Also, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the content clearly dictates otherwise. It should also be noted that the term "or" is generally used in its sense to include "and / or" unless the content clearly dictates otherwise.
[0031] 2.Definition As used in this specification and the appended claims, unless specified to the contrary, the following terms and abbreviations have the meanings indicated.
[0032] As used herein, the term "about" or "approximately" means within 20% of a given value or range. In some embodiments, the term "about" refers to within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of a given value.
[0033] As used herein, "Compound A" refers to a STAT3 degrader having the formula: [ka] refers to (2-(((5S,8S,10aR)-3-acetyl-8-(((S)-5-amino-1-(2-chloro-3-(4-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)phenoxy)-5-oxopentan-2-yl)carbamoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocin-5-yl)carbamoyl)-1H-indole-5-carbonyl)phosphonic acid. In some embodiments, Compound A is provided in a solid form. In some embodiments, Compound A is amorphous.
[0034] As used herein, "Compound A ammonium hydrogen salt" (also known as "Compound A ammonium salt") refers to a STAT3 degrader having the formula: [ka] represents ammonium hydrogen (2-(((5S,8S,10aR)-3-acetyl-8-(((S)-5-amino-1-(2-chloro-3-(4-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)phenoxy)-5-oxopentan-2-yl)carbamoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocin-5-yl)carbamoyl)-1H-indole-5-carbonyl)phosphonate. In some embodiments, Compound A ammonium hydrogen salt is provided in a solid form. In some embodiments, Compound A ammonium hydrogen salt is amorphous.
[0035] As used herein, the term "pharmaceutical acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., within the scope of sound medical judgment, and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutical acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic acids, inorganic bases, organic acids, and organic bases. Examples of pharma- ceutically acceptable, non-toxic acid addition salts are salts of amino groups formed with inorganic acids (e.g., hydrochloric, hydrobromic, phosphoric, sulfuric, and perchloric) or organic acids (e.g., acetic, oxalic, maleic, tartaric, citric, succinic, or malonic acids), or by using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, and the like. Examples of suitable salts include phosphate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, and valerate.
[0036] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1~4 Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharma- ceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations, formed where appropriate using counterions such as halides, hydroxides, carbonates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates.
[0037] The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human. As used herein, the term "subject" has the same meaning as the term "patient".
[0038] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset, or inhibiting the progression of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., taking into account a history of the symptoms and / or taking into account genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, e.g., to prevent or delay the recurrence of the symptoms.
[0039] As used herein, a patient or subject "in need of prophylaxis," "in need of treatment," or "in need of" refers to one who, as determined by a competent health care practitioner (e.g., in the case of humans, a physician, nurse, or nurse practitioner; in the case of non-human mammals, a veterinarian), would reasonably benefit from a given treatment or therapy.
[0040] A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent, such as Compound A, or a pharma- ceutically acceptable salt thereof, is any amount of drug that, when used alone or in combination with another therapeutic agent, protects a patient or subject from developing a disease, such as LGL-L, or promotes disease regression, as evidenced by a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or prevention of functional impairment or disability due to disease affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to those skilled in the art, such as by assaying the activity of the agent in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.
[0041] In a preferred embodiment, a therapeutically effective amount of a drug, such as compound A, promotes regression to the point of eliminating the disease. Furthermore, the terms "effective" and "effectiveness" in relation to treatment include both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of compound A or its pharmacologic acceptable salt to treat disease in patients. Physiological safety refers to the level of toxicity or other adverse physiological effects (adverse effects) at the cell, organ and / or organism level resulting from administration of the drug.
[0042] As used herein, the term "therapeutic benefit" or "benefit from treatment" refers to an improvement in one or more of overall survival, progression-free survival, partial response, complete response, and overall response rate, and can also include a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or prevention of impairment or disability due to the affliction of the disease.
[0043] The stages of "women of childbearing potential" (WOCBP) are: 1. after menarche; 2. considered reproductive from the time of menarche until postmenopause, unless permanently infertile. Postmenopausal status is defined as 12 months of amenorrhea without another medical cause. High follicle-stimulating hormone (FSH) levels in the postmenopausal range may be used to confirm postmenopausal status in women not using hormonal contraceptives or hormone replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required. Women on HRT and with questionable menopausal status will be required to use one of the non-estrogen hormonal highly effective methods of contraception if they wish to continue HRT during the trial. Otherwise, women on HRT and with questionable menopausal status must discontinue HRT to allow confirmation of postmenopausal status prior to enrollment in the trial. Permanent sterilization methods (for the purposes of this study) include documented hysterectomy; documented bilateral salpingectomy; documented bilateral oophorectomy. For individuals with permanent fertility due to another medical cause other than those listed above (e.g., Müllerian agenesis, androgen insensitivity, gonadal dysgenesis), the investigator's discretion should be applied in determining study participation.
[0044] 3. Description of Exemplary Embodiments: In some embodiments, the present invention provides a method for treating hematological and solid tumors in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, or a liquid formulation thereof, as described herein. In some embodiments, the hematological and solid tumors are relapsed and / or refractory lymphomas, large granular lymphocytic leukemias, and advanced solid tumors. In some embodiments, the hematological and solid tumors are selected from large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).
[0045] In some embodiments, the disclosure provides a method for treating hematological and solid tumors in a patient, such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutical acceptable salt or liquid formulation thereof, as described herein.
[0046] In some embodiments, the disclosure provides a method for treating LGL-L in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, or a liquid formulation thereof, as described herein.
[0047] In some embodiments, the disclosure provides a method for treating PTCL in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, or a liquid formulation thereof, as described herein.
[0048] In some embodiments, the disclosure provides a method for treating CTCL in a patient, comprising administering to the patient a therapeutically effective amount of Compound A, or a pharma- ceutically acceptable salt thereof, or a liquid formulation thereof, as described herein.
[0049] In some embodiments, the patient is male or female, aged 18 years or older.
[0050] In some embodiments, the patient has a histologically or pathologically confirmed lymphoma (including Hodgkin's lymphoma, B-cell lymphoma, T-cell lymphoma, small lymphocytic lymphoma or NK-cell lymphoma, or LGL-L) or solid tumor.
[0051] In some embodiments, the patient has histologically or pathologically confirmed PTCL, CTCL (WHO / EORTC classification), LGL-L [chronic lymphoproliferative disorder of T cells LGL-L or NK cells (CLPD-NK)] or a solid tumor.
[0052] In some embodiments, fresh or archived formalin-fixed paraffin-embedded (FFPE) tumor tissue or 15 slides are preferably obtained ideally within 6 months or 2 years prior to the first dose of investigational drug (for lymphoma and solid tumor patients, respectively). In some embodiments, if archived tissue / slides / blocks are not available, a pre-dose biopsy is performed (optional for Phase 1a, mandatory for Phase 1b) and blood samples are taken during screening for STAT3 pathway mutation analysis and potentially for central pathology review.
[0053] In some embodiments, the lymphoma or solid tumor patient has relapsed and / or refractory disease to at least two prior systemic standard of care treatments, or for which no standard of care is available.
[0054] In some embodiments, the LGL-L patient has relapsed and / or refractory disease to at least one prior systemic standard of care treatment, or no standard of care is available for the patient.
[0055] In some embodiments, patients of all disease types have relapsed and / or refractory disease to at least one prior systemic standard of care treatment, or for whom no standard of care is available.
[0056] In some embodiments, the LGL-L patient has a blood glucose level of 500 / mm 3 Have hematology-specific criteria selected from one of the following: less than severe neutropenia, symptomatic anemia and / or transfusion-dependent anemia; ANC ≥ 200 / μL at screening and C1D1 (pre-dose); or platelet count ≥ 100,000 / μL (in thrombocytopenic patients requiring platelets, assessed ≥ 7 days after last platelet transfusion).
[0057] In some embodiments, the LGL-L patient has a CD3+CD8+ cell population >650 / mm 3 CD3+CD8+CD57+ population >500 / mm 3 have baseline disease characteristics selected from the presence of clonal T-cell receptors (within 1 month of diagnosis) and 500 cells / mm 3 Natural killer (NK) LGLs are also acceptable if a clonal NK cell population recognized in the NK cell line is present.
[0058] In some embodiments, PTCL patients with solid tumors have measurable disease at screening according to Lugano for PTCL and Response evaluation criteria in solid tumors (RECIST) version 1.1 for solid tumors.
[0059] In some embodiments, patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at screening and C1D1 (pre-dosing).
[0060] In some embodiments, patients have adequate bone marrow function at screening and C1D1 (pre-dose), for all patients except those with LGL-L, defined as follows: absolute neutrophil count (ANC) > 1000 / μL; hemoglobin > 8 g / dL (for patients receiving red blood cell [RBC] transfusions, hemoglobin must be assessed at least 14 days after the last RBC transfusion); and platelet count > 100,000 / μL (for thrombocytopenic patients requiring platelets, assessed 7 or more days after the last platelet transfusion).
[0061] In some embodiments, patients with LGL-L have an ANC of 200 / μL or greater at screening and C1D1 (pre-dosing).
[0062] In some embodiments, patients have adequate organ function at screening and C1D1 (pre-dosing) for all patients, including those with LGL-L, including aspartate aminotransferase (AST), alanine transaminase (ALT) ≦3×upper limit of normal (ULN) or <5×ULN if documented lymphoma involving the liver; total serum bilirubin ≦3×ULN or <5×ULN if secondary to Gilbert's syndrome or if documented lymphoma involving the liver; and serum creatinine clearance ≧50 mL / min / 1.73 m2, measured or calculated using the standard Cockcroft-Gault formula.
[0063] In some embodiments, female patients of childbearing potential (WOCBP) must agree to use highly effective methods of contraception for the duration of treatment and for six months after the last dose of Compound A. In some embodiments, WOCBP must have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test within 72 hours prior to the first dose of Compound A.
[0064] In some embodiments, if the partner is a WOCBP, the male patient must agree to use highly effective methods of contraception during treatment and for six months after the last dose of Compound A.
[0065] In some embodiments, the patient has no history or suspicion of central nervous system (CNS) metastasis.
[0066] In some embodiments, the patient does not have a diagnosis of chronic lymphocytic leukemia (CLL).
[0067] In some embodiments, the patient has no history of active concurrent malignancies other than lymphoma or solid tumors, unless the patient has been disease-free for more than two years. Exceptions to the two-year or more deadline include treated basal cell or localized squamous cell skin cancer, localized prostate cancer, or other localized carcinomas such as intraepithelial carcinoma of the cervix, breast, or bladder.
[0068] In some embodiments, the patient has not recovered to pre-treatment baseline or Grade 1 from any clinically significant adverse events (AEs) of previous treatment prior to the first dose of Compound A.
[0069] In some embodiments, patients do not have ongoing unstable cardiovascular function: symptomatic ischemia, or uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic drugs would be excluded; first degree atrioventricular block or asymptomatic left anterior fascicle block / right bundle branch block would not be excluded), or New York Heart Association Class III or higher congestive heart failure, or myocardial infarction within 3 months prior to screening.
[0070] In some embodiments, patients do not have congenital long QT syndrome or a QT interval corrected by Fridericia's formula (QTcF) ≥ 450 ms (average of triplicate electrocardiograms) at Screening and / or C1D1 (pre-dosing), except for documented bundle branch block or secondary to a pacemaker.
[0071] In some embodiments, patients have no history of thromboembolic or cerebrovascular events (i.e., transient ischemic attack, cerebrovascular accident, pulmonary embolism, or clinically significant deep vein thrombosis) within two years prior to screening.
[0072] In some embodiments, the patient does not have an infection requiring an antibiotic, antiviral, or antifungal agent within one week prior to the first dose of Compound A. Prophylactic use of these agents may be acceptable, even if parenterally.
[0073] In some embodiments, the patient does not have active hepatitis B and / or hepatitis C infection as detected by positive hepatitis B surface antigen (HbsAg) or antibodies to hepatitis C virus (anti-HCV) with confirmatory tests (e.g., anti-HBc, IgM anti-HBc, anti-HBs, HCV RNA), known seropositivity for human immunodeficiency virus (HIV).
[0074] In some embodiments, the patient does not have a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test at the time of screening.
[0075] In some embodiments, the patient does not have any coexisting medical conditions, including psychiatric disorders, that, in the judgment of the investigator, interfere with the patient's ability to participate in the trial or achieve the objectives of the trial or pose a safety risk.
[0076] In some embodiments, the patient is not pregnant or lactating.
[0077] In some embodiments, the patient has not undergone an autologous hematopoietic stem cell transplant less than 3 months prior to the first dose of Compound A.
[0078] In some embodiments, the patient has not previously undergone an allogeneic hematopoietic or bone marrow transplant.
[0079] In some embodiments, the patient has not undergone radiation treatment within 4 weeks prior to the first dose of Compound A.
[0080] In some embodiments, the patient has not undergone major surgery requiring general anesthesia within four weeks prior to the first dose of Compound A.
[0081] In some embodiments, the patient has not received a live vaccine within one month prior to the first dose of Compound A.
[0082] In some embodiments, the patient has not been exposed to an investigational or non-investigational anti-cancer treatment within 4 weeks or at least 5 half-lives (up to a maximum of 4 weeks), whichever is shorter, prior to the first dose of Compound A. In all circumstances, the maximum drug holiday period will not exceed 4 weeks prior to the first dose of Compound A.
[0083] In some embodiments, the patient has not completed a course of SARS-CoV-2 vaccine within 14 days prior to the first dose of Compound A.
[0084] In some embodiments, the patient has not used a strong CYP3A4 inhibitor or inducer within 14 days or 5 half-lives (whichever is longer) of the first dose of Compound A) within the past 14 days prior to the first dose.
[0085] In some embodiments, the patient has not used an OATP1B inhibitor or inducer within 14 days or 5 half-lives (whichever is longer) of the first dose of Compound A) within the past 14 days prior to the first dose.
[0086] In some embodiments, the patient has not used OATP1B, BCRP, and CYP2C8 substrates with narrow therapeutic indices (as identified after review with a medical monitor) within 14 days or 5 half-lives (whichever is longer) of the first dose of Compound A (within the past 14 days prior to the first dose).
[0087] In some embodiments, the methods of the invention include intravenously administering a liquid formulation described herein. In some embodiments, the methods of the invention include administering a unit dosage form described herein. In some embodiments, the methods of the invention include administering a liquid formulation or a unit dosage form described herein daily to a patient.
[0088] Liquid formulations According to one embodiment, the present invention provides a liquid formulation comprising the STAT3 degrader of the present invention (e.g., compound A) or a pharma- ceutically acceptable derivative thereof and a pharma- ceutically acceptable excipient (e.g., buffer) and / or carrier (e.g., water). The amount of compound A in the liquid formulation of the present invention is such that it is effective to measurably degrade and / or inhibit STAT3 protein or a mutant thereof in a patient. In some embodiments, the liquid formulation of the present invention is formulated for administration to a patient in need of such a composition. In some embodiments, the composition of the present invention is formulated for parenteral (e.g., intravenous) administration to a patient.
[0089] In some embodiments, the liquid formulations of the invention contain Compound A or a pharma- ceutically acceptable salt thereof (e.g., Compound A ammonium hydrogen salt) at a concentration of about 0.5%-1.5% w / w of the total weight of the formulation. In some embodiments, the liquid formulations of the invention contain Compound A or a pharma- ceutically acceptable salt thereof (e.g., Compound A ammonium hydrogen salt) at a concentration of about 0.6%-1.4%, about 0.7%-1.3%, about 0.8%-1.2%, or about 0.9%-1.1% w / w of the total weight of the formulation. In some embodiments, the liquid formulation of the present invention comprises Compound A or a pharma- ceutically acceptable salt thereof (such as Compound A ammonium hydrogen salt) at a concentration of about 0.60%, about 0.65%, about 0.70%, about 0.75%, about 0.80%, about 0.85%, about 0.9%, about 0.95%, about 1.00%, about 1.05%, about 1.10%, about 1.15%, about 1.20%, about 1.25%, about 1.30%, about 1.35%, about 1.40%, about 1.45%, or about 1.50% w / w of the total weight of the formulation. In some embodiments, the liquid formulation of the present invention comprises Compound A at a concentration of about 0.995% w / w of the total weight of the formulation. In some embodiments, the liquid formulation of the present invention comprises Compound A ammonium hydrogen salt at a concentration of about 1.00% w / w of the total weight of the formulation.
[0090] In some embodiments, the liquid formulation of the present invention contains Compound A or a pharma- ceutically acceptable salt thereof (e.g., Compound A ammonium hydrogen salt) at a concentration of about 5-15 mg / mL. In some embodiments, the liquid formulation of the present invention contains Compound A or a pharma- ceutically acceptable salt thereof (e.g., Compound A ammonium hydrogen salt) at a concentration of about 6-14 mg / mL, about 6.5-13.5 mg / mL, about 7-13 mg / mL, about 7.5-12.5 mg / mL, about 8-12 mg / mL, about 8.5-11.5 mg / mL, about 9-11 mg / mL, or about 9.5-10.5 mg / mL. In some embodiments, the liquid formulation of the present invention comprises Compound A or a pharma- ceutically acceptable salt thereof (such as Compound A ammonium hydrogen salt) at a concentration of about 8 mg / mL, about 8.5 mg / mL, about 9 mg / mL, about 9.5 mg / mL, about 10 mg / mL, about 10.5 mg / mL, about 11 mg / mL, about 11.5 mg / mL, or about 12 mg / mL. In some embodiments, the liquid formulation of the present invention comprises Compound A at a concentration of about 10 mg / mL. In some embodiments, the liquid formulation of the present invention comprises Compound A ammonium hydrogen salt at a concentration of about 10.14 mg / mL.
[0091] The liquid formulations of the present invention may be administered parenterally by injection, infusion or implantation (intravenous, intramuscular, subcutaneous, etc.) as liquid formulations or in unit dosage forms, or via suitable delivery devices or implants containing conventional non-toxic pharma- ceutically acceptable carriers and adjuvants.
[0092] In some embodiments, the liquid formulations provided for parenteral use are provided in unit dosage form (e.g., in single-dose ampoules) or in vials containing several doses, into which suitable preservatives can be added (see below).Typically, such compositions can be prepared as injection preparations, e.g., solutions or suspensions; solid and liquid forms suitable for use in preparing solutions or suspensions by reconstitution or adding dilution media before injection; emulsions, such as water-in-oil (w / o) emulsions, oil-in-water (o / w) emulsions and microemulsions thereof, liposomes or emulsomes.In a preferred embodiment, the liquid formulation or its unit dosage form is administered intravenously.The preparation of such liquid formulations and unit dosage forms is described herein, such as in Example 3.
[0093] For intravenous administration, the liquid formulation or unit dosage form is packaged in a solution with one or more aqueous buffers. In some embodiments, the liquid formulation or unit dosage form is packaged in a solution with a sterile isotonic aqueous buffer. In some embodiments, the liquid formulation or unit dosage form is buffered at about pH 5-8 or about pH 6-7 for parenteral administration upon dilution. In some embodiments, the buffering agent is in an amount to adjust the pH of the liquid formulation or unit dosage form of the present invention to about 6-8. In some embodiments, the liquid formulation or unit dosage form provided is at about pH 6.5. In some embodiments, the liquid formulation or unit dosage form provided is at pH 6.5±0.3. In some embodiments, the liquid formulation or unit dosage form provided is at about pH 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, or about 7.0. In some embodiments, the pH of a provided liquid formulation or unit dosage form may be adjusted by adding trace amounts of acid (eg, 1 N hydrochloric acid) or base (eg, 1 N sodium hydroxide).
[0094] Suitable buffers or buffering agents include, but are not limited to, phosphate buffer, citrate buffer, acetate buffer, histidine buffer or succinate buffer.In some embodiments, the buffer is one or more phosphate buffers.In certain embodiments, the one or more phosphate buffers are disodium phosphate (e.g., disodium phosphate heptahydrate) and monosodium phosphate (e.g., monosodium phosphate monohydrate).
[0095] In some embodiments, the liquid formulation or unit dosage form of the present invention comprises a sodium phosphate buffer. In some embodiments, the liquid formulation or unit dosage form of the present invention comprises a sodium phosphate buffer at a concentration of about 25-75 mM, about 30-70 mM, about 35-65 mM, about 40-60 mM, or about 45-55 mM. In some embodiments, the liquid formulation or unit dosage form of the present invention comprises a sodium phosphate buffer at a concentration of about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, or about 75 mM. In some embodiments, the liquid formulation or unit dosage form of the present invention comprises a sodium phosphate buffer at a concentration of about 50 mM.
[0096] In some embodiments, the liquid formulations or unit dosage forms of the invention contain a sodium phosphate buffer in a concentration of about 0.2%-1.1% w / w of the total weight of the formulation, hi some embodiments, the liquid formulations or unit dosage forms of the invention contain a sodium phosphate buffer in a concentration of about 0.3%-1.0%, about 0.4%-0.9%, about 0.5%-0.8%, or about 0.6%-0.7% w / w of the total weight of the formulation. In some embodiments, the liquid formulation or unit dosage form of the present invention comprises a sodium phosphate buffer at a concentration of about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, about 1.0%, about 1.05%, or about 1.1% w / w of the total weight of the formulation. In some embodiments, the liquid formulation or unit dosage form of the present invention comprises a sodium phosphate buffer at a concentration of about 0.64% w / w of the total weight of the formulation. In some embodiments, the liquid formulation or unit dosage form of the present invention comprises a sodium phosphate buffer at a concentration of 0.636% w / w of the total weight of the formulation.
[0097] In some embodiments, the liquid formulation or unit dosage form of the invention comprises a sodium phosphate buffer at a concentration of about 2-11 mg / mL of the total weight of the formulation. In some embodiments, the liquid formulation or unit dosage form of the invention comprises a sodium phosphate buffer at a concentration of about 3-10, about 4-9, about 5-8, or about 6-7 mg / mL. In some embodiments, the liquid formulation or unit dosage form of the invention comprises a sodium phosphate buffer at a concentration of about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, or about 11 mg / mL. In some embodiments, the liquid formulation or unit dosage form of the invention comprises a sodium phosphate buffer at a concentration of about 6.4 mg / mL. In some embodiments, the liquid formulation or unit dosage form of the invention comprises a sodium phosphate buffer at a concentration of 6.36 mg / mL.
[0098] In some embodiments, the present invention provides a liquid formulation comprising Compound A at a concentration of about 0.995% w / w of the total weight of the formulation and sodium phosphate buffer at a concentration of about 50 mM, at about pH 6.5.
[0099] In some embodiments, the present invention provides a liquid formulation comprising Compound A at a concentration of about 10 mg / mL and sodium phosphate buffer at a concentration of about 50 mM, at a pH of about 6.5.
[0100] In some embodiments, the invention provides a liquid formulation comprising Compound A at a concentration of about 0.995% w / w of the total weight of the formulation and a sodium phosphate buffer at a concentration of about 0.64% w / w of the total weight of the formulation, at about pH 6.5.
[0101] In some embodiments, the present invention provides a liquid formulation comprising Compound A at a concentration of about 10 mg / mL and sodium phosphate buffer at a concentration of about 0.64% w / w of the total weight of the formulation, at about pH 6.5.
[0102] In some embodiments, the present invention provides a liquid formulation comprising Compound A at a concentration of about 0.995% w / w of the total weight of the formulation and sodium phosphate buffer at a concentration of about 6.4 mg / mL, at about pH 6.5.
[0103] In some embodiments, the present invention provides a liquid formulation comprising Compound A at a concentration of about 10 mg / mL and sodium phosphate buffer at a concentration of about 6.4 mg / mL, at a pH of about 6.5.
[0104] In some embodiments, the present invention provides a liquid formulation comprising Compound A ammonium hydrogen salt at a concentration of about 1.00% w / w of the total weight of the formulation and sodium phosphate buffer at a concentration of about 50 mM, at about pH 6.5.
[0105] In some embodiments, the present invention provides a liquid formulation comprising Compound A ammonium hydrogen salt at a concentration of about 10.14 mg / mL and sodium phosphate buffer at a concentration of about 50 mM, at a pH of about 6.5.
[0106] In some embodiments, the present invention provides a liquid formulation having a pH of about 6.5 comprising compound A ammonium hydrogen salt in a concentration of about 1.00% w / w of the total weight of the formulation and a sodium phosphate buffer in a concentration of about 0.64% w / w of the total weight of the formulation.
[0107] In some embodiments, the present invention provides a liquid formulation comprising Compound A ammonium hydrogen salt at a concentration of about 10.14 mg / mL and sodium phosphate buffer at a concentration of about 0.64% w / w of the total weight of the formulation, at about pH 6.5.
[0108] In some embodiments, the present invention provides a liquid formulation comprising Compound A ammonium hydrogen salt at a concentration of about 1.00% w / w of the total weight of the formulation and sodium phosphate buffer at a concentration of about 6.4 mg / mL, at about pH 6.5.
[0109] In some embodiments, the present invention provides a liquid formulation comprising Compound A ammonium hydrogen salt at a concentration of about 10.14 mg / mL and sodium phosphate buffer at a concentration of about 6.4 mg / mL, at a pH of about 6.5.
[0110] In some embodiments, the present invention provides a unit dosage form of the liquid formulation of the present invention, as described above, having a volume of about 10 mL. In some embodiments, the present invention provides a unit dosage form of the liquid formulation of the present invention, as described above, having a volume of about 10.5 mL. In some embodiments, the present invention provides a unit dosage form of the liquid formulation of the present invention, as described above, having a volume of about 10.1 mL, about 10.2 mL, about 10.3 mL, about 10.4 mL, about 10.6 mL, about 10.7 mL, about 10.8 mL, about 10.9 mL, about 11 mL, about 11.1 mL, about 11.2 mL, about 11.3 mL, about 11.4 mL, or about 11.5 mL.
[0111] In certain embodiments, the present invention provides a unit dosage form that can be prepared by combining 101.4 mg of Compound A ammonium hydrogen salt, 47.8 mg of disodium phosphate heptahydrate, 44.1 mg of sodium phosphate monobasic monohydrate, and water to a concentration of about 10 mg / mL of Compound A, and adjusting the pH to about 6.5 by adding hydrochloride acid and sodium hydroxide.
[0112] In certain embodiments, the present invention provides liquid formulations or unit dosage forms as described in the Examples herein, such as Example 3. In certain embodiments, the present invention provides liquid formulations or unit dosage forms that can be prepared by the processes as described in the Examples herein, such as Example 3. In some embodiments, the unit dosage form comprises a liquid volume of about 10 mL.
[0113] Liquid formulations may also contain solubilizing agents if necessary. The components of the formulation may be separate or mixed together in unit dosage form, for example, as dry lyophilized powder (which can be reconstituted with a carrier such as saline before use) or concentrated solution in a sealed container such as an ampoule or sachet indicating the amount of active agent. When the composition is administered by injection, the composition can be dispensed using an infusion bottle or bag containing sterile pharmaceutical grade water or saline. When the formulation is administered by injection, an ampoule of sterile water or saline can be provided so that the components can be mixed before injection.
[0114] Carrier can be, for example, solvent or dispersion medium containing water, ethanol, one or more polyols (for example, glycerol, propylene glycol and liquid polyethylene glycol), oil such as vegetable oil (for example, peanut oil, corn oil, sesame oil, etc.), and combinations thereof. Proper fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of dispersion, and / or by using surfactants. In many cases, it is preferred to include an isotonic agent, for example, sugar or sodium chloride. In a preferred embodiment, water is added to the formulation or unit dosage form of the present invention. In certain embodiments, the amount of water added to the formulation or unit dosage form is listed in Table 1 below.
[0115] Solutions and dispersions of the active compounds as a free acid or free base or a pharmacologically acceptable salt thereof may be prepared in water or another solvent or dispersion medium suitably mixed with one or more pharma- ceutically acceptable excipients including, but not limited to, buffers, surfactants, dispersing agents, emulsifying agents, viscosity modifiers, and combinations thereof.
[0116] Suitable surfactants may be anionic, cationic, amphoteric or nonionic surfactants. Suitable anionic surfactants include, but are not limited to, those containing carboxylate ions, sulfonate ions and sulfate ions. Examples of anionic surfactants include long chain alkyl sulfonates sodium, potassium, ammonium and alkylaryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates such as sodium bis-(2-ethylthiol)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate. Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine. Examples of nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbate, polyoxyethylene octylphenyl ether, PEG-1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, Poloxamer® 401, stearoyl monoisopropanolamide and polyoxyethylene hydrogenated tallow amide. Examples of amphoteric surfactants include sodium N-dodecyl-β-alanine, sodium N-lauryl-β-iminodipropionate, myristamphoacetate, lauryl betaine and lauryl sulfobetaine. The formulation may contain a preservative to prevent microbial growth. Suitable preservatives include, but are not limited to, parabens, chlorobutanol, phenol, sorbic acid and thimerosal. The formulation may also contain an antioxidant to prevent the degradation of the active agent.
[0117] Water soluble polymers are often used in formulations for parenteral administration. Suitable water soluble polymers include, but are not limited to, polyvinylpyrrolidone, dextran, carboxymethylcellulose, and polyethylene glycol.
[0118] Sterile injectable solutions can be prepared by incorporating the required amount of active compound into a suitable solvent or dispersion medium with one or more of the excipients listed above as necessary, followed by filtration sterilization.Generally, dispersions are prepared by incorporating various sterilized active ingredients into a sterile vehicle that contains a basic dispersion medium and other required ingredients from those listed above.In the case of sterile powders for preparing sterile injectable solutions, the preferred preparation method is vacuum drying and freeze-drying technology, which gives a powder of active ingredients plus any additional desired ingredients from its previously sterile filtered solution.Powder can be prepared so that the particles are inherently porous, which can increase the dissolution of the particles.The method for producing porous particles is well known in the art.
[0119] In some embodiments, the liquid formulation or unit dose form of the present invention is mixed with an IV infusion vehicle. In some embodiments, the liquid formulation or unit dose form is mixed with an injection vehicle such as saline (0.9% sodium chloride), 5% dextrose (D5W) or lactated Ringer's injection. In some embodiments, the present invention provides a liquid pharmaceutical composition prepared by mixing the liquid formulation or unit dose form of the present invention with water and then diluting with saline or 5% dextrose. In some embodiments, the liquid pharmaceutical composition is diluted into a saline or 5% dextrose IV bag for IV administration. In some embodiments, the liquid pharmaceutical composition in the saline or 5% dextrose IV bag is stored under room temperature (about 20-25° C.) for up to about 4 hours prior to IV administration. In some embodiments, the liquid pharmaceutical composition in the saline or 5% dextrose IV bag is stored under refrigerated (about 2-8° C.) conditions for up to about 20 hours prior to IV administration. In some embodiments, the liquid pharmaceutical composition in the saline or 5% dextrose IV bag is stored under refrigerated (about 2-8° C.) conditions for up to about 20 hours, followed by storage at room temperature (about 20-25° C.) for up to about 4 hours prior to IV administration.
[0120] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound used, age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, as well as the judgment of the attending physician and the severity of the specific disease being treated. The amount of the compound of the present invention in the composition will also depend on the specific STAT3 degrading agent in the composition.
[0121] In some embodiments, the liquid formulation or unit dosage form of the present invention is a stabilized liquid formulation or stabilized unit dosage form. In some embodiments, the liquid formulation or unit dosage form of the present invention is in frozen form. In some embodiments, the liquid formulation or unit dosage form of the present invention is stable after three freeze / thaw cycles. In some embodiments, the liquid formulation or unit dosage form of the present invention is stable at 2-8°C for at least 3 months. In some embodiments, the liquid formulation or unit dosage form of the present invention is stable at -20°C for at least 12 months. In some embodiments, the stability of the liquid formulation or unit dosage form of the present invention is shown in Example 4 below.
[0122] Dosing and Schedule As provided in light of the preclinical data described herein, the STAT3 degrading agent (e.g., Compound A) or its pharma- ceutically acceptable salt, or pharmaceutical composition thereof, is administered to the patient at an appropriate dose and schedule to provide the desired cancer regression effect with minimal side effects. In some embodiments, the method of the present invention comprises administering to the patient daily up to about 3.0 mg / kg or up to about 5.0 mg / kg of Compound A (e.g., up to 201 mg or 350 mg for a 70 kg patient), such as about 0.25 mg / kg, about 0.5 mg / kg, about 0.75 mg / kg, about 1.0 mg / kg, about 1.5 mg / kg, about 2.0 mg / kg, about 2.5 mg / kg, about 3.0 mg / kg, about 3.5 mg / kg, about 4.0 mg / kg, or about 4.5 mg / kg of Compound A. In certain embodiments, the amount of Compound A administered to a patient daily is about 0.05, about 0.1, about 0.2, about 0.4, about 0.7, about 1.1, about 1.5, about 2.0 or about 2.7 mg / kg. In certain embodiments, the amount of Compound A administered to a patient daily is listed in Table 8 below.
[0123] In some embodiments, the method of the present invention includes administering to the patient daily up to about 500 mg of Compound A, e.g., up to about 25 mg, up to about 50 mg, up to about 75 mg, up to about 100 mg, up to about 150 mg, up to about 200 mg, up to about 300 mg, up to about 400 mg, or up to about 500 mg of Compound A. In some embodiments, the method of the present invention includes administering to the patient daily about 10 to 500 mg (e.g., about 10 to 400 mg, about 50 to 400 mg, about 100 to 400 mg, about 200 to 400 mg, about 50 to 300 mg, about 100 to 300 mg, about 200 to 300 mg, about 25 to 200 mg, about 75 to 200 mg, about 100 to 200 mg, about 150 to 300 mg, or about 200 to 400 mg). In some embodiments, the method of the present invention comprises administering to the patient about 50 mg of Compound A, e.g., a 0.5×100 mg unit dosage form, daily. In some embodiments, the method of the present invention comprises administering to the patient about 100 mg of Compound A, e.g., a 1×100 mg unit dosage form, daily. In some embodiments, the method of the present invention comprises administering to the patient about 150 mg of Compound A, e.g., a 1.5×100 mg unit dosage form, daily. In some embodiments, the method of the present invention comprises administering to the patient about 200 mg of Compound A, e.g., a 2×100 mg unit dosage form, daily. In some embodiments, the method of the present invention comprises administering to the patient about 250 mg of Compound A, e.g., a 2.5×100 mg unit dosage form, daily. In some embodiments, the method of the present invention comprises administering to the patient about 300 mg of Compound A, e.g., a 3×100 mg unit dosage form, daily. In some embodiments, the method of the present invention comprises administering about 350 mg of Compound A, e.g., 3.5×100 mg unit dosage form, to a patient daily. In some embodiments, the method of the present invention comprises administering about 400 mg of Compound A, e.g., 4×100 mg unit dosage form, to a patient daily. In some embodiments, the method of the present invention comprises administering a liquid formulation or unit dosage form described herein once a day. In some embodiments, the method of the present invention comprises administering a formulation or unit dosage form described herein twice a day.In some embodiments, the methods of the invention comprise administering a formulation or unit dosage form described herein three times per day, hi some embodiments, the methods of the invention comprise administering a formulation or unit dosage form described herein four to fourteen times per day.
[0124] In some embodiments, when a patient is administered about 200 mg of Compound A or a pharma- ceutically acceptable salt thereof daily, dosing is twice daily or BID, i.e., two separate doses of about 100 mg. In some embodiments, when a patient is administered about 300 mg of Compound A or a pharma- ceutically acceptable salt thereof daily, dosing is three times daily or TID, i.e., three separate doses of about 100 mg. In some embodiments, when a patient is administered about 400 mg of Compound A or a pharma- ceutically acceptable salt thereof daily, dosing is four times daily or QID, i.e., four separate doses of about 100 mg.
[0125] In some embodiments, the methods of the invention comprise administering a liquid formulation or unit dosage form described herein, wherein there are about 4 to 24 hours between two successive administrations, hi some embodiments, there are about 4, about 6, about 8, about 12, about 18, or about 24 hours between two successive administrations.
[0126] In some embodiments, the method of the invention comprises administering a liquid formulation or unit dosage form described herein, wherein there is about 1 to 7 days between two consecutive administrations. In some embodiments, there is about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days between two consecutive administrations. In certain embodiments, the liquid formulation or unit dosage form described herein is administered every 7 days between two consecutive administrations.
[0127] In some embodiments, the methods of the invention include administering a liquid formulation or unit dosage form described herein, wherein there is about 1-4 weeks between two consecutive administrations. In some embodiments, there is about 1, about 2, about 3, or about 4 weeks between two consecutive administrations. In some embodiments, the liquid formulation or unit dosage form described herein is administered once every two weeks (Q2W).
[0128] In some embodiments, compound A is administered to a patient once every 1, 2, 3, 4, 5, 6 or 7 days. In some embodiments, the liquid formulation or unit dosage form of the present invention is administered to a patient every other week (BIW). The biweekly doses can be administered several hours (e.g., 1, 3, 6, 12 hours) apart or days (e.g., 1, 2, 3, or 4 days) apart. In some embodiments, the biweekly doses are administered on days 1 and 2. In some embodiments, the biweekly doses are administered on days 1 and 4. In certain embodiments, the liquid formulation or unit dosage form described herein is administered once a week (QW). In some embodiments, compound A is administered intravenously and administered to a patient once every 1, 2, 3, or 4 weeks, or once every 7, 10, 14, 17, 21, 24, or 28 days. In some embodiments, the liquid formulation or unit dosage form described herein is administered once every two weeks (Q2W).
[0129] As described herein, in some embodiments, the liquid formulation or unit dosage form is administered once a week for 2 or 3 weeks out of 4 weeks. In some embodiments, the liquid formulation or unit dosage form is administered twice a week for 2 or 3 weeks out of 4 weeks. In some embodiments, the liquid formulation or unit dosage form is administered once a week for 2 weeks out of 3 weeks. In some embodiments, the liquid formulation or unit dosage form is administered twice a week for 2 weeks out of 3 weeks. In some embodiments, the liquid formulation or unit dosage form is administered once a week for every other week out of 4 weeks. In some embodiments, the liquid formulation or unit dosage form is administered twice a week for every other week out of 4 weeks.
[0130] In some embodiments, the liquid formulation or unit dosage form is administered to the patient once a week for weeks 1 and 2 of a three week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient once a week for weeks 1 and 2 of a four week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient once a week for weeks 1 and 2 of a four week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient once a week for weeks 1 and 3 of a four week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient once a week for weeks 1 to 3 of a four week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient once a week for weeks 1 to 4 of a four week administration cycle (e.g., on days 1, 8, 15, and 22 of a 28 day cycle).
[0131] In some embodiments, the liquid formulation or unit dosage form is administered to the patient twice weekly during weeks 1 and 2 of a three week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient twice weekly during weeks 1 and 2 of a four week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient once weekly during weeks 1 and 2 of a four week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient twice weekly during weeks 1 and 3 of a four week administration cycle. In some embodiments, the liquid formulation or unit dosage form is administered to the patient twice weekly during weeks 1 to 3 of a four week administration cycle. In some embodiments, the dosing schedule is shown in FIG. 4.
[0132] In some embodiments, the IV infusion of the unit dosage form of the present invention lasts for about 5 to 180 minutes. In some embodiments, the IV infusion of the pharmaceutical composition of the present invention lasts for about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, or 180 minutes, or any range of times created by using two of the above times as endpoints. In some embodiments, the IV infusion of the unit dosage form of the present invention lasts for about 60 to 120 minutes. In some embodiments, the IV infusion of the unit dosage form of the present invention lasts for about 120 to 180 minutes. In some embodiments, IV infusion of a unit dosage form of the present invention lasts for about 1, 2, 2.5, 3, 3.5 or 4 hours. In some embodiments, IV infusion of a unit dosage form of the present invention lasts for about 2 hours.
[0133] 4. Methods and Uses for Treating Disease In some embodiments, the present invention provides a method for treating a hematological malignancy (such as various leukemias and lymphomas) or a solid tumor in a patient, comprising administering to the patient a therapeutically effective amount of Compound A. In some embodiments, the hematological malignancy or solid tumor disease is large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), or cutaneous T-cell lymphoma (CTCL).
[0134] In some embodiments, the disclosure provides a method for treating a hematological malignancy in a patient, comprising administering to the patient a therapeutically effective amount of Compound A. In some embodiments, the hematological malignancy is leukemia, diffuse large B-cell lymphoma (DLBCL), ABC DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion lymphoma, Burkitt's lymphoma / leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, multiple myeloma, plasmacytoma, intravascular large B-cell lymphoma, AML, or MDS.
[0135] In some embodiments, the disclosure provides a method for treating relapsed or refractory lymphoma in a patient, comprising administering a therapeutically effective amount of Compound A to the patient.
[0136] In some embodiments, the disclosure provides a method for treating a solid tumor in a patient, comprising administering a therapeutically effective amount of Compound A to the patient.
[0137] In some embodiments, the disclosure provides a method for treating LGL-L in a patient, comprising administering a therapeutically effective amount of Compound A to the patient.
[0138] In some embodiments, the disclosure provides a method for treating PTCL in a patient, comprising administering a therapeutically effective amount of Compound A to the patient.
[0139] In some embodiments, the disclosure provides a method for treating CTCL in a patient, comprising administering a therapeutically effective amount of Compound A to the patient.
[0140] Without being limited to any particular theory, the present invention relates to a method for treating benign or malignant tumors, carcinomas or solid tumors of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, cervix, testes, genitourinary tract, esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastoma, neuroblastoma, multiple myeloma, gastrointestinal cancer, in particular colon cancer or colorectal adenoma, head and neck tumors, epidermal hyperproliferation, psoriasis, prostatic hyperplasia, neoplasia of epithelial character, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small cell lung cancer, lymphoma, Hodgkin's or non-Hodgkin's, breast cancer, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, IL-1 driven disorder, The present invention provides a method for treating a proliferative disease selected from leukemia, diffuse large B-cell lymphoma (DLBCL), ABC DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion lymphoma, Burkitt's lymphoma / leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, multiple myeloma, plasmacytoma, intravascular large B-cell lymphoma.
[0141] In some embodiments, the cancer that can be treated according to the method of the present invention is selected from glioma, breast cancer, prostate cancer, head and neck squamous cell carcinoma, cutaneous melanoma, and ovarian cancer. In some embodiments, aberrant STAT3 activation is also correlated with the progression of various hematopoietic malignancies, such as various leukemias and lymphomas, and STAT3 is frequently activated in both multiple myeloma cell lines and tumor cell lines derived from patient bone marrow.
[0142] In some embodiments, the present invention provides methods of treating a cancer selected from glioma, breast cancer, prostate cancer, head and neck squamous cell carcinoma, cutaneous melanoma, ovarian cancer, malignant peripheral nerve sheath tumors (MPNST), pancreatic cancer, urothelial cancer, liver cancer, cholangiocarcinoma, renal cancer, colon cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumors, and hematological malignancies including lymphoma, leukemia, myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.
[0143] In some embodiments, the present invention provides a method for treating JAK-associated disease.In some embodiments, JAK-associated disease is cancer, including those characterized by solid tumors (e.g., prostate cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, glioblastoma, Kaposi's sarcoma, Castleman's disease, uterine leiomyosarcoma, melanoma, etc.), blood cancers (e.g., lymphoma, leukemia, e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) or multiple myeloma), and skin cancers, such as cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma.Examples of CTCL include Sézary syndrome and mycosis fungoides.
[0144] In some embodiments, the invention provides methods of treating histologically or pathologically confirmed lymphoma (including Hodgkin's lymphoma, B cell lymphoma, T cell lymphoma, small lymphocytic lymphoma, or NK cell lymphoma). In some embodiments, the invention provides methods of treating histologically or pathologically confirmed PTCL, CTCL, LGL-L [chronic lymphoproliferative disorder of T cells LGL-L or NK cells (CLPD-NK)], or solid tumors.
[0145] 5. Processes and Intermediates In some embodiments, the present invention provides a process for preparing an ammonium hydrogen salt of Compound A. In some embodiments, the process for preparing an ammonium hydrogen salt of Compound A comprises the steps of: [ka] under suitable salt exchange conditions to form Compound A ammonium hydrogen salt.
[0146] In some embodiments, suitable salt exchange conditions used to prepare Compound A ammonium hydrogen salt from intermediate F include conditions known in the art for exchanging a DIPEA salt with an ammonium salt. In some embodiments, suitable salt exchange conditions include subjecting intermediate F to an ammonium source, such as a solution containing ammonium bicarbonate. In some embodiments, suitable salt exchange conditions are described in the Examples herein, e.g., Example 1.
[0147] In some embodiments, the process for preparing compound A ammonium hydrogen salt further comprises preparing intermediate F, which process comprises preparing intermediate D: [ka] of, Intermediate E: [ka] to form intermediate F.
[0148] In some embodiments, the process for preparing intermediate F from intermediates D and F further comprises a base, such as DIPEA. In some embodiments, the method for preparing intermediate F from intermediates D and F is described in the Examples herein, e.g., Example 1.
[0149] In some intermediate embodiments, the present invention provides a DIPEA salt of compound A (intermediate F): [ka] to provide.
[0150] The following examples are provided for illustrative purposes only and should not be construed as limiting the invention in any way. EXAMPLES
[0151] List of abbreviations AE Adverse Event ALCL Anaplastic large cell lymphoma ALT alanine aminotransferase ANC Absolute Neutrophil Count AST Aspartate transaminase AUC area under the concentration-time curve BSA body surface area CHOP Cyclophosphamide, doxorubicin, vincristine and prednisone CL Apparent total body clearance Cmax Maximum plasma drug concentration CNS Central Nervous System COVID-19 Coronavirus Disease 2019 CR Complete response CRBN Celebron eCRF Electronic Case Report Form CRO Contract Research Organization CT Computed Tomography CTCL Cutaneous T-cell lymphoma ctDNA Circulating tumor DNA CYP Cytochrome P450 C1D1 Cycle 1 Day 1 C2D1 Cycle 2 Day 1 DCR Disease control rate DDI Drug-Drug Interactions DLT dose-limiting toxicity DNA deoxyribonucleic acid DOR Duration of response DRF dose setting ECG Electrocardiogram ECOG Eastern Cooperative Oncology Group EDC Electronic Data Collection EMA European Medicines Agency End of OI injection EOT End of procedure FDA Food and Drug Administration fe Percentage excreted / recovered in urine FFPE Formalin-fixed Paraffin-embedded FFS treatment response maintenance survival (Failure-free survival) FIH First in Human FSH Follicle-stimulating hormone GCP Good Clinical Practice Standards GLP Good Laboratory Practice HBcAb Hepatitis C core antibody HBsAg Hepatitis B surface antigen HCV Hepatitis C virus HIV Human Immunodeficiency Virus HRT Hormone Replacement Therapy IB Investigator's Brochure ICF Informed Consent Form ICH International Conference for Harmonisation IEC Independent Ethics Committee IMiD Immunomodulatory Imido Drug INR International Normalized Ratio IRB Institutional Review Board IV Intravenous JAK Janu Kinase LAR Legally Authorized Representative LGL-L large granular lymphocytic leukemia LHRH Luteinizing hormone releasing hormone MAD Maximum Administered Dose MF mycosis fungoides MRI Magnetic Resonance Imaging mSWAT Modified severity-weighted assessment tool MTD maximum tolerated dose NCI TCAE National Cancer Institute Common Terminology Criteria for Adverse Events NHL Non-Hodgkin's Lymphoma NK Natural Killer NTL Non-target lesion OR Objective response ORR Objective Response Rate OS overall survival PBMC peripheral blood mononuclear cells PD Pharmacodynamics PET Positron Emission Tomography PFS Progression-free survival PK Pharmacokinetics PR partial response PTCL Peripheral T-cell lymphoma PTCL-NOS PTCL not otherwise specified qs (sufficient amount) QTcF QT interval corrected by Fridericia's formula QW Once a week RBC Red blood cell RECIST Response Evaluation Criteria in Solid Tumors RP2D Recommended Phase 2 Dose R / R Relapsed / Refractory SAE Serious Adverse Event SAP Statistical Analysis Plan SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 SRC Safety Review Committee SS Sézary syndrome STAT signal transducer and activator of transcription SUSAR Suspected Unexpected Serious Adverse Reaction t 1 / 2 Elimination half-life TEAE Treatment-emergent adverse events TL target lesion tmax The time to reach Cmax after drug administration LN Upper limit UPS Ubiquitin Proteosome System US Vd Apparent volume of distribution Vdss Volume of distribution at steady state WHO World Health Organization WHODD World Health Organization Drug Dictionary WOCBP Women of childbearing potential
[0152] Example 1. Synthesis of Compound A Compound A can be prepared by methods known to those skilled in the art, for example, as described in WO 2020 / 206424, the contents of which are incorporated herein by reference in their entirety, including intermediates A, B, C, D and E below. [ka] [ka]
[0153] Step 1. Preparation of intermediate C. To a room temperature solution of amine A, acid B and 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) in dichloromethane, 4-methylmorpholine (NMM) was added slowly. The reaction mixture was stirred at this temperature until complete conversion of A to C was achieved (reaction conversion monitoring by IPC, HPLC). Once the reaction was complete, deionized water was added. The layers were separated and the organic phase was washed successively with aqueous solutions of monosodium phosphate, sodium bicarbonate and sodium chloride. The organic layer was dried over magnesium sulfate and the filtrate was tested for water content (IPC for water content by KF). The organic stream was concentrated and the resulting solution was used directly in step 2 (IPC, purity and HPLC assays).
[0154] Step 2. Preparation of intermediate D. To a cold solution of intermediate C in dichloromethane (DCM) was slowly added a solution of hydrochloric acid in dioxane. The reaction mixture was allowed to warm to room temperature for at least 5 hours. Upon completion of the reaction (reaction monitoring by IPC, HPLC), the resulting solid was filtered, rinsed with DCM, and dried (IPC, water content by KF, purity by HPLC, and residual solvent by GC).
[0155] Step 3. Preparation of intermediate F. To a cold suspension of the HCl salt of intermediate D in MeCN, N,N-diisopropylethylamine (DIPEA) was added, followed by a solution of intermediate E in N-methylpyrrolidinone (NMP) and a second charge of DIPEA. The reaction mixture was warmed to room temperature and stirred until complete conversion of intermediate D to F was achieved (reaction conversion monitoring by IPC, HPLC). The reaction mixture was slowly transferred to a room temperature solution of MeCN to precipitate the DIPEA salt of compound A (intermediate F). The suspension was then stirred at room temperature for at least 1 hour before being filtered. The filtered solid was rinsed with MeCN and dried (IPC, purity by HPLC, residual solvent by GC).
[0156] Step 3'. Preparation of Compound A ammonium hydrogen salt. Intermediate F was purified by reverse phase preparative chromatography using ammonium bicarbonate and MeCN as eluents (IPC, fractional purity by HPLC). The relevant fractions were combined and concentrated. The combined relevant fractions were concentrated (IPC, purity by HPLC) and lyophilized to give Compound A ammonium hydrogen salt (IPC, water content by KF, residual solvent (MeCN) by GC, residual solvent (NMP and DIPEA) by GC).
[0157] Example 2. In vivo xenograft model The antitumor efficacy of Compound A ammonium hydrogen salt was evaluated in immunocompromised mice transplanted with human ALCL cell lines SU-DHL-1 and SUP-M2. Protocols for testing STAT3 degraders in human cell line xenograft models can be found, for example, in International Publication No. WO 2020 / 206424, which is incorporated herein by reference.
[0158] SU-DHL-1 The antitumor activity of compound A ammonium hydrogen salt was evaluated in a human SU-DHL-1 cell line xenograft model established in NOD SCID female mice. Tumor-bearing mice (n=5 / group) were administered 0 (vehicle; PBS), 5, 10, 15 or 45 mg / kg of compound A once a week (QW; days 0, 7 and 14) or 0 (vehicle; PBS), 10 or 30 mg / kg of compound A once every two weeks (Q2W; days 0 and 14). Animals administered compound A QW were monitored until day 25 after the first dose, and animals administered compound A Q2W were monitored until day 71 after the first dose.
[0159] All animals in the control groups (QW and Q2W) were euthanized on days 25 and 19, respectively, due to tumor burden. Overall, slight to moderate weight gain was observed in animals administered Compound A by the IV route.
[0160] Compound A-associated antitumor activity was observed in a dose-dependent manner for all treatment groups: animals receiving an IV dose of 5 mg / kg Compound A QW achieved 79.9% tumor growth inhibition (TGI), whereas animals receiving 10, 15, or 45 mg / kg Compound A QW all achieved complete regressions that were sustained until the end of the study (Figure 1A).
[0161] Administration of Compound A Q2W at 10 and 30 mg / kg achieved 89.8 and 99.8% TGI, respectively, and all animals in the 30 mg / kg Q2W group achieved complete tumor regression that was sustained until the end of the study (Figure 1B). These data support the feasibility of intermittent dosing of Compound A by the IV route.
[0162] SUP-M2 The antitumor activity of compound A ammonium hydrogen salt was evaluated in a human SUP-M2 cell line xenograft model established in NOD SCID female mice. Tumor-bearing mice (n=5 / group) were administered 0 (vehicle; PBS), 10, 20 or 30 mg / kg compound A QW (days 0, 7 and 14), 10 or 20 mg / kg compound A on a 2-day on / 5-day off schedule (days 0, 1, 7, 8, 14 and 15), or 0 (vehicle; PBS), 20 or 40 mg / kg compound A Q2W (days 0 and 14). Animals administered compound A QW or 2 on / 5 off were monitored until day 25 after the first dose, and animals administered compound A Q2W were monitored until day 52 after the first dose.
[0163] All animals in the control groups (QW and Q2W) were euthanized early on days 19 and 20 due to tumor burden, respectively. Overall, little to no weight gain was observed in animals administered Compound A by the IV route.
[0164] Compound A showed significant dose-dependent antitumor activity in SUP-M2 xenografts. Animals receiving an IV dose of Compound A at 10 mg / kg QW achieved 83.8% TGI, whereas animals receiving 20 and 30 mg / kg QW achieved complete tumor regression in 4 of 5 and 5 of 5 animals, respectively, which was sustained until the end of the study (Figure 2A). Administration of Compound A at 10 and 20 mg / kg in a 2 day on / 5 day off regimen achieved complete tumor regression in all animals, which was sustained until the end of the study (Figure 2A). Administration of Compound A at 20 and 40 mg / kg Q2W achieved complete tumor regression in 4 of 5 and 5 of 5 animals, respectively, which was sustained until the end of the study (Figure 2B).
[0165] Example 3. Drug Products The drug product, Compound A Injection (Concentrated Solution for Infusion), consists of a clear, colorless solution of Compound A in a clear, Type I glass vial fitted with a rubber stopper and sealed with a flip-off aluminum cap. The drug product is formulated as 10 mg / mL of Compound A free acid (equivalent to 10.14 mg / mL of the ammonium salt) dissolved in water for injection (WFI) containing sodium phosphate dihydrate heptahydrate and sodium phosphate monohydrate, adjusted to a target pH of 6.5 with either hydrochloric acid (HCl) or sodium hydroxide (NaOH).
[0166] The label fill volume is 10 mL. Each glass vial contains a minimum of 10.5 mL of sterile Compound A solution designed to deliver a nominal 10.0 mL of solution. The drug product solution is intended to be diluted with diluent to the required concentration for intravenous infusion.
[0167] The quantitative composition of the drug products is shown in Table 1. [Table 1] a Based on the free acid (1.000 mg of Compound A free acid is equivalent to 1.014 mg of Compound A hydrogen ammonium salt). bTo ensure a nominal recovery of 10.0 mL of solution, the United States Pharmacopeia <1151> A minimum overfill of 0.5 mL is included in accordance with the
[0168] The drug product is manufactured by dissolving Compound A (off-white amorphous solid) in a solution of WFI, disodium phosphate heptahydrate and monosodium phosphate monohydrate. The final pH is adjusted to 6.5±0.3 with HCl / NaOH and brought to 10 mg / ml with appropriate amount of WFI. The solution is made in a 20 L glass vessel with stirring. The prepared solution is filtered through two sterile filters mounted in series to obtain a sterile solution. The sterile solution is then filled into glass vials, stoppered and aseptically crimped. Each vial is filled by weight to contain 10.5 mL of sterile solution. The final product is 100% visually inspected and labeled. The vials are cooled to ensure uniform freezing at -20°C. A flow diagram of the manufacturing process is shown in Figure 3.
[0169] Example 4. Formulation Development Compound A Injection was manufactured as a frozen concentrated solution containing 10 mg / mL of the free acid that is intended to be diluted with an IV infusion vehicle. Compound A Injection has an aqueous solubility of greater than 10 mg / mL at pH 4.5-9.0, but less than 10 mg / mL at a pH of 3 or less.
[0170] An R&D stability evaluation was performed on a solution formulation containing 10 mg / mL of Compound A free acid dissolved in phosphate buffer at a pH range between 4.5 and 7.4. After storage for 14 days at -20°C, 5°C, room temperature (RT), and 40°C, assay and impurity results demonstrated that Compound A solutions were chemically and physically stable at 5°C and -20°C. A slight increase in impurities was observed when Compound A solutions were stored at RT, pH 4.5. Additionally, significant degradation was observed when Compound A solutions were stored at 40°C, pH 4.5-7.4.
[0171] Further stability studies were performed on Compound A, 10 mg / mL solutions in phosphate buffer within a narrower pH range of 5.0-7.0 stored at -20°C, 5°C, room temperature, and 40°C. Chemical testing after 30 days showed no significant increase in impurities when stored at -20°C, 5°C, and room temperature. However, significant impurity increase was detected at 40°C within pH 5.0-7.0. Due to these observations, the pH of Compound A solution formulation for scale-up development was selected to be 6.5±0.5, and the long-term storage condition was selected to be -20°C as a frozen solution to ensure sufficient long-term chemical and physical stability could be achieved.
[0172] As part of the development work, a buffer screening study was performed. To demonstrate acceptable short-term stability of compound A solutions, several 50 mM buffers were examined, including phosphate (pH 6.5), citrate (pH 6.5), histidine (pH 6.5) and succinate (pH 6.0). Compound A solutions at 10 mg / mL in the different buffer types were stored at -20°C, 2-8°C, 25°C and 40°C. After 14 days, changes in assay and impurity profile were minimal up to 25°C and comparable across the buffers evaluated. However, significant color changes were observed in histidine and succinate buffers when stored for 7 days at 40°C storage conditions. For all evaluated buffers, impurities began to increase after 3 days at 40°C. As satisfactory stability results were obtained with compound A solutions in phosphate buffer and no significant advantage was observed with other buffer types, R&D-scale development was pursued using 50 mM phosphate buffer at pH 6.5 ± 0.5.
[0173] The compatibility of Compound A at 10 mg / mL in 50 mM phosphate buffer, pH 6.5 with three different IV infusion vehicles was evaluated: saline (0.9% sodium chloride), 5% dextrose (D5W) and lactated Ringer's injection. Based on visual appearance, pH, assay and impurity results, saline was selected as the diluent for IV infusion administration of Compound A solution.
[0174] Since the long-term storage of Compound A solution, 10 mg / mL is at -20°C, the freeze-thaw stability was investigated for a frozen solution of Compound A solution, 10 mg / mL in 50 mM phosphate buffer, pH 6.5±0.5. The results illustrated that after a total of three freeze-thaw cycles, all vials showed no changes in appearance, pH, assay, and impurities compared to the initial ones.
[0175] An R&D batch of Compound A, 10 mg / mL, solution in 50 mM phosphate buffer (disodium phosphate and monosodium phosphate) at pH 6.5 ± 0.5 was produced. Results from a stability study of this R&D batch demonstrate that the Compound A solution formulation was chemically and physically stable (i.e., the Compound A solution formulation was clear, colorless, and free of visible particulates) for 18 months when stored at -20°C, 4 months at 2-8°C, and 2 months at 25°C.
[0176] Based on the formulation development work discussed above, a 15.5 liter GMP batch containing 10 mg / mL Compound A free acid in 50 mM phosphate buffer, pH 6.5 ± 0.5, was manufactured to support first-in-human studies.
[0177] As shown in Table 2, a 12-month study was conducted on samples from the GMP batch at -20°C, confirming stability and sterility at 12 months. [Table 2]
[0178] Container closure system: The drug product was sterile filtered and filled into glass vials fitted with stoppers equipped with Flurotec barrier film secured by flip-cap aluminum seals.
[0179] Microbiological Properties: Drug products were manufactured aseptically and tested for bacterial endotoxins and sterility for release and stability.
[0180] Compatibility: Stability / compatibility studies of frozen concentrated IV dosing solutions were conducted for Compound A Injection. These studies were designed to mimic the expected conditions, supplies, and procedures to be maintained during preparation of dosing solutions in a clinical environment. In the clinic, each frozen dose of Compound A Injection 10 mg / mL is completely thawed at room temperature. The volume of the thawed drug product solution is then calculated for addition to an appropriately sized saline IV bag based on the intended patient dose. The final diluted dosing solution is then administered to the patient via IV infusion over a 1-2 hour period.
[0181] Compound A Injection Freeze-Thaw (FT) Study: To assess the stability of the thawed drug product, a laboratory experiment was conducted under conditions representative of those found during clinical dose preparation. First, each required vial of Compound A Injection was removed from the -20°C freezer and thawed under room temperature laboratory lighting.
[0182] The freeze-thaw stability was investigated for frozen Compound A injection, 10 mg / mL. Four vials, labeled as FT-T0, FT-1x, FT-2x, and FT-3x, were assigned to the study. The FT-T0 vial was tested first and served as the reference. The remaining three vials were subjected to freeze-thaw (FT) cycles. Each FT cycle involved freezing the drug product vial at -20°C for 24 hours, followed by complete thawing at room temperature.
[0183] After 24 hours of freezing, all three vials (FT-1x, FT-2x, and FT-3x) were thawed at room temperature. The FT-1x vial was pulled for testing. The remaining two vials (FT-2x and FT-3x) were then subjected to a second freezing again for 24 hours. After thawing, FT-2x was pulled and tested for a second freeze-thaw cycle. The remaining vial (FT-3x) was subjected to a final FT cycle. All vials were tested for appearance, pH, assay, and impurities.
[0184] The results, presented in Table 3, Compound A Injection, 10 mg / mL, indicate acceptable physicochemical stability for at least three FT cycles. All stability parameters for FT-1x, FT-2x and FT3x were comparable to the initial sample (FT-T0) and remained well within established drug product specifications for each FT cycle. [Table 3]
[0185] Compound A Injection IV Dosing Solution: Laboratory studies were conducted under conditions representative of clinical dose preparation to evaluate the stability and compatibility of Compound A Injection IV Dosing Solution with the IV administration supplies (bags, tubing, and close system transfer devices) intended for use in clinical trials. The IV bags, administration sets (tubing), and closed system transfer devices (CSTDs) utilized in this study are shown in Table 4. [Table 4]
[0186] To accommodate the range of final clinical doses, studies were conducted with "bracketing" IV bag solution concentrations of 2 and 0.03 mg / mL (1000 and 15 mg equivalents). To prepare the IV dosing solutions, each required vial of Compound A for Injection (100 mg drug / 10 mL) was thawed for at least 1 hour under ambient laboratory lighting and temperature conditions. The appropriate volume of drug product was then calculated to achieve either 2 or 0.03 mg / mL (1000 and 15 mg equivalents) in a 500 cc IV bag. An equal volume of saline was first removed from the IV bag and discarded prior to adding the calculated volume of drug product.
[0187] Once the drug product solution was added to the IV bag, the resulting diluted IV dosing solution was mixed thoroughly by hand and kept under ambient laboratory lighting and temperature conditions for the duration of the study. Samples were then drawn from the IV bag port via syringe at 0, 8, 24 and 48 hours. These samples were then tested for stability-indicating parameters, including appearance, pH and assay / impurities.
[0188] Meanwhile, at time 0, for the 2 mg / mL drug solution, an IV infusion set (tubing) with an air removal filter extension and catheter was connected to an IV bag and filled with drug saline (primed). After the IV tubing was filled with drug solution, the catheter end of the IV tubing was lifted to stop the flow of drug solution, the IV tubing was removed from the IV bag, and both ends of the IV tubing were lifted in a "U" position to keep the diluted drug saline solution inside the IV tubing and allow full contact between the drug solution and the IV tubing during the stationary phase as the worst case scenario. At 8 hours, the drug solution in the IV tubing was then analyzed.
[0189] For the 0.03 mg / mL concentration IV solution, the IV tubing with filter and catheter was flushed (filled and drained) four times with approximately 20 mL of drug solution per flush. For each flush fraction, the drug solution was collected and analyzed for the assay to determine any assay degradation of Compound A in the IV tubing. After four flushes, the IV tubing was then filled with drug solution, the catheter end of the IV tubing was raised to stop the flow of drug solution, the IV tubing was removed from the IV bag, and both ends of the IV tubing were raised in a "U" position to hold the diluted drug saline solution in the IV tubing and allow full contact between the drug solution and the IV tubing during the resting phase as a worst case scenario. At 8 hours, the drug solution in the IV tubing was then analyzed.
[0190] Compound A Injection Dosing Solution (2 mg / mL) in IV Bags and Infusion Tubing: As shown in Table 5, the 2 mg / mL concentration IV dosing solution prepared in IV bags and filled into IV tubing demonstrated acceptable physicochemical stability and compatibility up to 48 hours and 8 hours, respectively. All stability parameters remained within established product specifications at each time point and showed little or no change. [Table 5]
[0191] Compound A Injection Dosing Solution (0.03 mg / mL) in IV Bag: As shown in Table 6, the IV dosing solution at a concentration of 0.03 mg / mL prepared in an IV bag demonstrated acceptable physicochemical stability and compatibility for up to 48 hours. In a study of IV infusion tubing with a filter and catheter, the assay appeared to drop by 12% in the first flush fraction, indicating that Compound A may have been adsorbed to the IV tubing after the first flush with 20 mL of drug solution. However, the % assay approached 100% with 2-4 flushes and after 8 hours of drug solution retention in the IV administration set. These results indicated that the amount of Compound A adsorbed to the IV administration set was minimal and occurred only in the first 20 mL of the 0.03 mg / mL drug solution. [Table 6]
[0192] All stability parameters remained within established product specifications at each time point and showed little or no change (Table 7). However, impurity levels in the diluted Compound A solution at 0.03 mg / mL were too low and below the detection limit of the release assay / impurity method, so total impurities could not be determined. [Table 7]
[0193] Conclusion: Data from this study indicate that Compound A Injection frozen solutions, 10 mg / mL, exhibit acceptable physicochemical stability after three cycles of freezing for 24 hours and complete thawing at room temperature. Similarly, simulated Compound A Injection solutions for IV dosing solutions at "extreme" concentrations of 0.03 and 2 mg / mL also exhibit acceptable stability under ambient storage conditions in IV bags and IV fusion tubing for up to 48 hours and 8 hours, respectively. Furthermore, results from these studies suggest acceptable compatibility of Compound A Injection with the intended diluent (0.9% saline) and containment / administration system (commercially available IV bags / tubing) used in the clinical setting.
[0194] Example 5. A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered Compound A in Adult Patients with Relapsed or Refractory Lymphoma, Large Granular Lymphocyte Leukemia, and Solid Tumors Rationale: Targeted protein degraders represent a new therapeutic class of compounds that utilize the ubiquitin proteasome system to target the specific degradation of proteins. Compound A is a protein degrader that targets signal transducer and activator of transcription (STAT) 3, a transcription factor that plays an important role in hematological malignancies such as lymphomas and solid tumors. Compound A will be administered by intravenous infusion (IV) at dose levels defined in the protocol on days 1, 8, 15, and 22 of each 28-day cycle.
[0195] Objectives and Evaluation Items: [Table A] [Table B]
[0196] Overall Design: This is an open-label, Phase 1a (dose escalation) / Phase 1b (dose expansion) first-in-human trial of Compound A in adult patients with relapsed / refractory (R / R) lymphoma, LGL-L or advanced solid tumors. The primary objective of the Phase 1a portion of this study is to identify the maximum tolerated dose [MTD] / recommended Phase 2 dose [RP2D]. Phase 1b will consist of separate cohorts of patients with R / R peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGL-L) and solid tumors.
[0197] Patients who provide informed consent and meet the eligibility criteria for this study will be enrolled and treated with Compound A IV on days 1, 8, 15, and 22 of a 28-day cycle. Patients will remain on study treatment until disease progression, unacceptable toxicity, withdrawal of consent, any study-specific discontinuation criteria are met, or the investigator determines that it is in the patient's best interest to discontinue study treatment.
[0198] Obtain fresh / archived FFPE tumor tissue. If archived tissue / slides / blocks are not available, perform a pre-dose biopsy (optional for Phase 1a, mandatory for Phase 1b). One in-treatment biopsy is required in Phase 1b unless medically contraindicated or unattainable due to lack of feasibility. This biopsy is optional for Phase 1a. Additional biopsies at the time of disease progression are optional for all patients. Any issues with collecting biopsies should be discussed with the medical monitor. End of treatment / safety follow-up visits are scheduled within 30 days of the last dose of Compound A and prior to the initiation of a new anticancer therapy, whichever occurs first. Additionally, patients will be contacted every 3 months to collect data regarding survival status and subsequent treatments for up to 1 year after the last dose of Compound A.
[0199] Up to approximately 40 evaluable patients will be enrolled in Phase 1a, with the total number of patients depending on the number of dose levels being investigated. Each cohort in Phase 1b will enroll up to 20 evaluable patients. A schematic of the trial is provided in Figure 2.
[0200] Phase 1a: This part aims to characterize the safety and tolerability of IV weekly doses of Compound A in sequential cohorts. The dose escalation phase will be conducted in patients with R / R lymphoma, LGL-L or advanced tumors and will utilize a 3+3 design after accelerated titration, with the ultimate goal of defining the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D).
[0201] After determination of the MTD / RP2D, doses will be confirmed prior to initiating enrollment into each cohort in Phase 1b (R / R lymphoma or LGL-L in cohorts 1, 2 and 3, and advanced solid tumors in cohort 4).
[0202] Enrollment in Phase 1b may not begin until the following criteria are met: 1) A total of at least 9 patients must have been treated at the MTD / RP2D, and 2) At least 6 patients with R / R lymphoma and advanced solid tumors must have been treated at the MTD / RP2D for each cohort to begin enrollment in Phase 1b. 3) A total of at least 3 LGL-L patients have been treated to initiate enrollment in Phase 1b.
[0203] Enrollment in the lymphoma, LGL-L and solid tumor cohorts may begin independently as soon as criteria are met for each cohort.
[0204] It is planned to evaluate approximately nine dose levels of Compound A. The planned doses are shown in Table 8. [Table 8] a Planned dose levels are shown. Doses may be adjusted higher or lower based on emerging safety / PK / PD data from this study as determined by the SRC.b If dose reduction is required in the first cohort, lower doses may be explored as recommended by the SRC.
[0205] The safety of ongoing patient escalation dose levels and dose escalation will be determined by the Safety Review Committee (SRC) based on review of all available data, including but not limited to safety and pharmacokinetics (PK).
[0206] Once the MTD / RP2D has been determined in 3–6 patients, the MTD / RP2D will be confirmed by enrolling additional R / R lymphoma, LGL-L and advanced solid tumor patients until a total of 9 patients have been enrolled prior to the start of Phase 1b (see above).
[0207] Phase 1b, Dose Expansion: After establishing the RP2D in patients with R / R lymphoma, LGL-1 and solid tumors, up to 80 additional patients will be treated in the following cohorts to further characterize treatment-emergent adverse events (TEAEs) and to evaluate the relative clinical activity of Compound A. Cohort 1: PTCL (all subtypes of PTCL except CTCL) (n=max 20) Cohort 2: CTCL (n=max 20) Cohort 3: LGL-L (n=max 20) Cohort 4: Solid tumors (n=max 20)
[0208] Phase 1b expansion may begin at separate time points in cohorts 1-3 and cohort 4, depending on when the RP2D was established in the R / R lymphoma, LGL-L, and solid tumor confirmatory portions of Phase 1a. Patients will be treated at the RP2D determined in each patient population in Phase 1a. The starting dose in patients in cohort 3 (LGL-L) is the RP2D determined in lymphoma, LGL-L, and solid tumor patients in Phase 1a. If DLTs in lymphoma across all patients are primarily hematologic (i.e., neutropenia) or infectious in nature, a starting dose below the RP2D alternating regimen (e.g., IV every 2 weeks) or a lower dose evaluated in LGL-L patients after discussion with the SRC may be used.
[0209] Patient safety will be monitored throughout the study by an SRC established by the sponsor. This committee will continually monitor all treatment-emergent data, including PK and safety (including but not limited to DLTs), to ensure the ongoing safety of patients enrolled in the study. Cumulative data will be monitored for any delayed toxicities.
[0210] Study population Inclusion criteria
[0211] Patients are eligible to be included in the study only if all of the following criteria are met: 1. Male or female, aged 18 years or older on the date of signing the informed consent. 2. Patients will understand and provide a signed and dated written informed consent and will voluntarily consent prior to any mandatory study-specific procedures, sample collection and analysis. Patients will be able to give signed informed consent that includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and this protocol. 3. Phase 1a only: Histologically or pathologically confirmed lymphoma, including: Hodgkin, ·B cells, ·T cells, Small lymphocytic or NK cell lymphoma LGL-L (see inclusion numbers 7, 9, and 10) Histologically or pathologically confirmed solid tumors. 4. Phase 1b only: Histologically or pathologically confirmed PTCL, CTCL (WHO / EORTC classification), LGL-L [chronic lymphoproliferative disorder of T-cells LGL-L or NK cells (CLPD-NK) - see inclusion numbers 7, 9, 10] or solid tumors. 5. Preferably, fresh or archived formalin-fixed paraffin-embedded (FFPE) tumor tissue or 15 slides, ideally taken within 6 months or 2 years prior to the first dose of investigational drug (for lymphoma and solid tumor patients, respectively). If archived tissue / slides / blocks are not available, a pre-dose biopsy will be performed (optional for Phase 1a, mandatory for Phase 1b) and blood samples will be taken during screening for STAT3 pathway mutation analysis and potentially for central pathology review. 6. Phase 1a only: Lymphomas and solid tumors: Relapsed and / or refractory disease to at least two prior systemic standard of care treatments, or for whom no standard of care is available. 7. Phase 1a: LGL-L: Relapsed and / or refractory disease to at least one prior systemic standard of care treatment, or for whom no standard of care is available. 8. Phase 1b only: All disease types: Relapsed and / or refractory disease to at least one prior systemic standard of care treatment or for whom no standard of care is available. 9. For LGL-L patients only: (Hematology-specific criteria): One of the following: Severe neutropenia <500 / mm 3 ,or Symptomatic anemia and / or ○Blood transfusion-dependent anemia. ANC ≥ 200 / μL at screening and C1D1 (pre-medication) Platelet count ≥ 100,000 / μL (in thrombocytopenic patients requiring platelets, assessed ≥ 7 days after last platelet transfusion). 10. LGL-L patients only (baseline disease characteristics): CD3+CD8+ cell population >650 / mm 3 ; CD3+CD8+CD57+ population >500 / mm 3 ; · Presence of clonal T-cell receptors (within 1 month of diagnosis); Note: +TCR is required even if the CD3+CD8+ cell population is <650 / mm 3 or CD3+CD8+CD57+ population <500 / mm 3 Even so, patients with T-LGLL may be enrolled with PI approval. ·500 cells / mm 3 Natural killer (NK) LGLs are also acceptable if there is a clonal NK cell population recognized beyond the NK cell population. 11. PTCL and solid tumors only: At screening, measurable disease by Lugano for PTCL and by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for solid tumors. 12. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at screening and C1D1 (pre-dose). 13. Adequate bone marrow function at Screening and C1D1 (pre-dose) for all patients except those with LGL-L, defined as follows: Absolute neutrophil count (ANC) ≥ 1000 / μL Hemoglobin ≥ 8 g / dL (for patients receiving red blood cell [RBC] transfusions, hemoglobin must be assessed at least 14 days after the last RBC transfusion). Platelet count ≥ 100,000 / μL (in thrombocytopenic patients requiring platelets, assessed ≥ 7 days after last platelet transfusion). 14. Adequate organ function at screening and C1D1 (before dosing) for all patients, including those with LGL-L Aspartate aminotransferase (AST) and alanine transaminase (ALT) levels less than 3 times the upper limit of normal (ULN) or less than 5 times the ULN in patients with documented lymphoma of the liver Total serum bilirubin ≤3x the ULN or ≤5x the ULN if secondary to Gilbert syndrome or documented concurrent lymphoma of the liver. Serum creatinine clearance ≥ 50 mL / min / 1.73 m2, measured or calculated using the standard Cockcroft-Gault formula 15. Women of childbearing potential (WOCBP) must agree to use highly effective methods of contraception for the duration of study treatment and for 6 months after the last dose of Compound A. 16. WOCBP must have a negative serum pregnancy test at screening and a negative serum or urine pregnancy test within 72 hours prior to the first dose of study drug. 17. If partner is WOCBP, male must agree to use highly effective methods of contraception during study treatment and for 6 months after the last dose of study drug.
[0212] Exclusion criteria Patients will be excluded from the study if they meet any of the following criteria: 1. History or suspicion of central nervous system (CNS) metastases. 2. Diagnosis of chronic lymphocytic leukemia (CLL). 3. History of malignancy or active intercurrent malignancy other than lymphoma or solid tumors, unless the patient has been disease-free for ≥2 years. Exceptions to the ≥2 year limit include treated basal cell or localized squamous cell skin cancer, localized prostate cancer, or other localized carcinomas such as carcinoma in situ of the cervix, breast, or bladder. 4. Patients have not recovered from any clinically significant adverse events (AEs) of previous treatment to pre-treatment baseline or Grade 1 prior to the first dose of study drug. 5. Ongoing unstable cardiovascular function: Symptomatic ischemia, or Uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic drugs would be excluded; first-degree atrioventricular block or asymptomatic left anterior fascicle block / right bundle branch block would not be excluded), or New York Heart Association Class III or higher congestive heart failure, or Myocardial infarction within 3 months prior to screening. 6. Congenital long QT syndrome or QT interval corrected by Fridericia's formula (QTcF) ≥ 450 ms (average of triplicate ECGs) at Screening and / or C1D1 (pre-dose) except for documented bundle branch block or secondary to a pacemaker. In the case of documented bundle branch block or pacemaker, discussion with the medical monitor is required prior to enrollment. 7. History of thromboembolic or cerebrovascular events (i.e., transient ischemic attack, cerebrovascular accident, pulmonary embolism, or clinically significant deep vein thrombosis) within 2 years prior to screening. 8. Infection requiring antibiotics, antivirals or antifungals within 1 week prior to the first dose of study drug. Prophylactic use of these agents is acceptable, even if parenteral. 9. Active hepatitis B and / or hepatitis C infection as detected by positive hepatitis B surface antigen (HbsAg) or antibody to hepatitis C virus (anti-HCV) with confirmatory testing (e.g., anti-HBc, IgM anti-HBc, anti-HBs, HCV RNA), known seropositivity for human immunodeficiency virus (HIV). 10. Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test at screening. 11. Any coexisting medical condition, including psychiatric disorder, that, in the investigator's judgment, interferes with the patient's ability to participate in the study or achieve the objectives of the study or poses a safety risk. 12. The patient is pregnant or breastfeeding. 13. Autologous hematopoietic stem cell transplant <3 months prior to first dose of investigational drug. 14. Previous allogeneic hematopoietic or bone marrow transplant. 15. Radiation treatment within 4 weeks prior to the first dose of study drug. 16. Major surgery requiring general anesthesia within 4 weeks prior to first dose of study drug. If a patient has required general anesthesia within the past 4 weeks, a consultation with the medical monitor is required prior to enrollment. 17. Received a live vaccine within 1 month prior to the first dose of the investigational drug. 18. Exposure to investigational or non-investigational anti-cancer treatment within 4 weeks or at least 5 half-lives (up to a maximum of 4 weeks), whichever is shorter, prior to the first dose of an investigational drug. In all circumstances, the maximum drug-free period will not exceed 4 weeks prior to the first dose of an investigational drug. Note: Prior hormonal therapy with low-dose steroids (oral prednisone or equivalent ≤ 20 mg / day), local non-CNS radiation therapy, luteinizing hormone-releasing hormone agonists for prostate cancer, and treatment with bisphosphonates and RANKL inhibitors are not exclusion criteria. 18. Patient has completed one course of SARS-CoV-2 vaccine within 14 days prior to the first dose of investigational drug. 19. Use of a strong CYP3A4 inhibitor or inducer within 14 days or 5 half-lives (whichever is longer) of the first dose of an investigational drug (within the past 14 days). 20. Use of an OATP1B inhibitor or inducer within 14 days or 5 half-lives (whichever is longer) of the first dose of an investigational drug (within the past 14 days). 21. Use of OATP1B, BCRP and CYP2C8 substrates with narrow therapeutic index (as identified after discussion with the medical monitor) within 14 days or 5 half-lives (whichever is longer) of the first dose of an investigational drug (within the past 14 days). 22. Patient is unable or unwilling to discontinue prohibited concomitant medications or is unable or unwilling to comply with restrictions on concomitant medication use. 23. Patient is unable or unwilling to comply with all requirements of this study. 24. Any person who is committed to the institution by public or judicial order. 25. Staff of the sponsor or investigator's facilities who are directly involved in the conduct of this study, and staff of other facilities supervised by the investigator, and their respective families.
[0213] Statistical considerations No formal statistical hypotheses will be tested in this dose escalation and dose expansion, single treatment arm trial. Safety, efficacy, PK and pharmacodynamic assessments will be summarized separately for the dose escalation and dose expansion portions of the study. Additional summaries of pooled data across dose levels and / or expansion cohorts may also be generated. Descriptive and summary statistics will be presented for evaluation and will include number of observations, mean, standard deviation, median and range for continuous variables, whereas categorical data will be summarized using frequency counts and percentages. Listings and graphical summaries of data may be presented. All details of data summaries and presentations will be presented in a formal statistical analysis plan that will be compiled prior to final database lock.
[0214] Preliminary results Blood STAT3 degradation at the first dose level was consistent with preclinical predictions, with an average maximum degradation of 66% and a maximum knockdown of 86% after the first two doses in cycle 1. Target degradation for at least 72 hours was observed, which resulted in robust antitumor activity in STAT3-sensitive models in preclinical species.
[0215] The DL1 level was safe and well tolerated with no DLTs or SAEs.
[0216] Figure 5 shows PK data from four patients enrolled in DL1. Figure 6 shows STAT3 degradation in blood at DL1. The 50-80% STAT3 degradation observed in PBMCs at dose level 1 is consistent with the range predicted for tumors based on preclinical modeling of SUDHL1 xenograft PK-PD data. As seen in preclinical models, maximal degradation was observed between 24-96 hours post-infusion in weeks 1 and 2 of cycle 1, with recovery of STAT3 levels observed between doses.
[0217] While the inventors have described several embodiments of the invention, it is apparent that the inventors' basic examples may be modified to provide other embodiments that utilize the compounds and methods of the invention. It will therefore be appreciated that the scope of the invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.
Claims
1. A liquid formulation comprising Compound A or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient and / or carrier, Compound A is (2-(((5S,8S,10aR)-3-acetyl-8-(((S)-5-amino-1-(2-chloro-3-(4-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)phenoxy)-5-oxopentan-2-yl)carbamoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocin-5-yl)carbamoyl)-1H-indole-5-carbonyl)phosphonic acid, a liquid formulation.
2. 2. The liquid formulation of claim 1, comprising Compound A at a concentration of about 0.995% w / w of the total weight of the formulation.
3. 2. The liquid formulation of claim 1, comprising Compound A ammonium hydrogen salt in a concentration of about 1.00% w / w of the total weight of the formulation.
4. 2. The liquid formulation of claim 1, comprising Compound A at a concentration of about 10 mg / mL.
5. 2. The liquid formulation of claim 1, comprising Compound A ammonium hydrogen salt at a concentration of about 10.14 mg / mL.
6. 6. The liquid formulation of any one of claims 1 to 5, comprising a sodium phosphate buffer at a concentration of about 50 mM.
7. 6. The liquid formulation of any one of claims 1 to 5, comprising a sodium phosphate buffer in a concentration of about 0.64% w / w of the total weight of the formulation.
8. 6. The liquid formulation of any one of claims 1 to 5, comprising a sodium phosphate buffer at a concentration of about 6.4 mg / mL.
9. The liquid formulation according to any one of claims 1 to 8, having a pH of about 6.
5.
10. A liquid formulation according to any one of claims 1 to 9, which is a formulation selected from the following: 1) a liquid formulation comprising Compound A in a concentration of about 0.995% w / w of the total weight of said formulation and a sodium phosphate buffer in a concentration of about 50 mM, said liquid formulation having a pH of about 6.5; 2) a liquid formulation comprising Compound A at a concentration of about 10 mg / mL and sodium phosphate buffer at a concentration of about 50 mM, at about pH 6.5; 3) a liquid formulation having a pH of about 6.5 comprising Compound A in a concentration of about 0.995% w / w of the total weight of the formulation and a sodium phosphate buffer in a concentration of about 0.64% w / w of the total weight of the formulation; 4) a liquid formulation comprising Compound A in a concentration of about 10 mg / mL and a sodium phosphate buffer in a concentration of about 0.64% w / w of the total weight of the formulation, said liquid formulation having a pH of about 6.5; 5) a liquid formulation comprising Compound A in a concentration of about 0.995% w / w of the total weight of the formulation and sodium phosphate buffer in a concentration of about 6.4 mg / mL, at about pH 6.5; 6) A liquid formulation comprising Compound A in the concentration of about 10 mg / mL and sodium phosphate buffer in the concentration of about 6.4 mg / mL, at about pH 6.5; 7) a liquid formulation comprising Compound A ammonium hydrogen salt in a concentration of about 1.00% w / w of the total weight of the formulation and sodium phosphate buffer in a concentration of about 50 mM, at about pH 6.5; 8) A liquid formulation comprising Compound A ammonium hydrogen salt at a concentration of about 10.14 mg / mL and sodium phosphate buffer at a concentration of about 50 mM, having a pH of about 6.5; 9) a liquid formulation having a pH of about 6.5 comprising Compound A ammonium hydrogen salt in a concentration of about 1.00% w / w of the total weight of the formulation and a sodium phosphate buffer in a concentration of about 0.64% w / w of the total weight of the formulation; 10) A liquid formulation comprising Compound A ammonium hydrogen salt in a concentration of about 10.14 mg / mL and sodium phosphate buffer in a concentration of about 0.64% w / w of the total weight of the formulation, said liquid formulation having a pH of about 6.5; 11) A liquid formulation having a pH of about 6.5 comprising Compound A ammonium hydrogen salt in a concentration of about 1.00% w / w of the total weight of the formulation and a sodium phosphate buffer in a concentration of about 6.4 mg / mL; and 12) A liquid formulation comprising Compound A ammonium hydrogen salt in a concentration of about 10.14 mg / mL and sodium phosphate buffer in a concentration of about 6.4 mg / mL, having a pH of about 6.
5.
11. The liquid formulation according to any one of claims 1 to 10, which is a unit dosage form having a volume of about 10 mL.
12. 12. A method for treating a hematological malignancy or solid tumor in a patient, comprising administering to the patient a therapeutically effective amount of a liquid formulation according to any one of claims 1 to 11.
13. 13. The method of claim 12, wherein the hematological malignancy or solid tumor is a relapsed or refractory lymphoma.
14. 13. The method of claim 12, wherein the hematological malignancy or solid tumor is selected from large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
15. 15. The method of any one of claims 12 to 14, wherein the method comprises administering up to about 3.0 mg / kg of Compound A per day to the patient.
16. 15. The method of any one of claims 12 to 14, wherein the method comprises administering up to about 500 mg of Compound A per day to the patient.
17. 17. The method of any one of claims 12 to 16, wherein the method comprises administering Compound A intravenously to the patient.
18. 18. The method of any one of claims 12 to 17, wherein the method comprises administering Compound A to the patient once a week (QW).
19. 19. The method of any one of claims 12 to 18, wherein the method comprises administering Compound A to the patient on days 1, 8, 15 and 22 of a 28 day cycle.
